HelixADMET: a robust and endpoint extensible ADMET system incorporating self-supervised knowledge transfer
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Motivation: Accurate ADMET (an abbreviation for ‘absorption, distribution, metabolism, excretion and toxicity’) predictions can efficiently screen out undesirable drug candidates in the early stage of drug discovery. In recent years, multiple comprehensive ADMET systems that adopt advanced machine learning models have been developed, providing services to estimate multiple endpoints. However, those ADMET systems usually suffer from weak extrapolation ability. First, due to the lack of labelled data for each endpoint, typical machine learning models perform frail for the molecules with unobserved scaffolds. Second, most systems only provide fixed built-in endpoints and cannot be customized to satisfy various research requirements. To this end, we develop a robust and endpoint extensible ADMET system, HelixADMET (H-ADMET). H-ADMET incorporates the concept of self-supervised learning to produce a robust pre-trained model. The model is then fine-tuned with a multi-task and multi-stage framework to transfer knowledge between ADMET endpoints, auxiliary tasks and self-supervised tasks. Results: Our results demonstrate that H-ADMET achieves an overall improvement of 4%, compared with existing ADMET systems on comparable endpoints. Additionally, the pre-trained model provided by H-ADMET can be fine-tuned to generate new and customized ADMET endpoints, meeting various demands of drug research and development requirements. Availability and implementation: H-ADMET is freely accessible at https://paddlehelix.baidu.com/app/drug/admet/train. Supplementary information: Supplementary data are available at Bioinformatics online.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“These basic endpoints constituted the input for calculating drug-likeness rules of medicinal chemistry, such as the Lipinski ruleof-five (26) and the Ghose and Veber rules (27, 28).”
MethodDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
PubChem in 2021: new data content and improved web interfaces
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa971 · Cited by 3,953
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835 · cited 1×
“cut-offs and have limitations in their applications–oral drugs that break some of the rules are also increasingly reported (58, 59).”
BackgroundTrends in clinical success rates and therapeutic focus
Dowden, H., & Munro, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00074-z · Cited by 649 · cited 1×
“INTRODUCTION The modern drug discovery process is extremely time-consuming and expensive, and yet, only 10-20% of drug candidates can make it to the market (1, 2).”
BackgroundThe Tox21 robotic platform for the assessment of environmental chemicals – from vision to reality
Attene-Ramos, M. S., Miller, N., Huang, R., Michael, S., Itkin, M., Kavlock, R. J., Austin, C. P., Shinn, P., Simeonov, A., Tice, R. R., et al. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.015 · Cited by 255
Bender, A., & Cortes-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.037 · Cited by 232
Cited by
Machine Learning Methods for Small Data Challenges in Molecular Science
Dou, B., Zhu, Z., Merkurjev, E., Ke, L., Chen, L., Jiang, J., Zhu, Y., Liu, J., Zhang, B., & Wei, G.-W. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00189 · Cited by 499
Amorim, A. M. B., Piochi, L. F., Gaspar, A. T., Preto, A. J., Rosário-Ferreira, N., & Moreira, I. S. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.3c00352 · Cited by 132
“ADMETLAB2, 48 FP-ADMET, 49 Interpretable ADMET, 22 and HelixAMDET 23 are general methods used to predict several ADMET end points.”
MethodRecent advances in AI-based toxicity prediction for drug discovery
Lee, H., Kim, J., Kim, J.-W., & Lee, Y. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1632046 · Cited by 76
(2024) · doi:10.1007/s00203-024-04140-y · Cited by 2
Metadata
- Authors
- Zhang, S., Yan, Z., Huang, Y., Liu, L., He, D., Wang, W., Fang, X., Zhang, X., Wang, F., Wu, H., & Wang, H.
- Venue
- Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-05-23
- Volume
- 38
- Issue
- 13
- Pages
- 3444-3453
- ISSN
- 1367-4803 (ISSN-L)
- 1367-4811
- OpenAlex
- W4280521575
- Cited by
- 60
- References
- 10
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.